Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

New Device Retrieves Circulating Tumor Cells Without Biochemical Labeling

By BiotechDaily International staff writers
Posted on 18 Jun 2013
Image: The ClearCell FX System for retrieval of circulating tumor cells. (Photo courtesy of Clearbridge BioMedics).
Image: The ClearCell FX System for retrieval of circulating tumor cells. (Photo courtesy of Clearbridge BioMedics).
A new device has been developed for improved cancer diagnosis and monitoring, without biochemical markers, that uses a noninvasive “liquid biopsy” approach for cancer screening, diagnosis, staging, personalized medication, and treatment monitoring.

Clearbridge BioMedics (Singapore) introduces its “ClearCell FX System,” a new generation cancer diagnostic and monitoring device that rapidly detects and isolates intact circulating tumor cells (CTCs) from small quantities of patient blood samples. The ClearCell FX System technology separates and isolates cells by using novel inertia focusing spiral microfluidics in the single-use “CTChip FR.” This enables the continuous label-free separation—without biochemical labels—of CTCs from blood cells. The larger and denser CTCs are separated from other blood cells within the spiral biochip due to biomechanical differences and are then focused into an enriched cell “stream.” These cell streams are channeled and collected into an enriched sample, which can be used for pathology diagnostic tests such as mutation testing for targeted therapies. The isolated CTCs can be stained for identification and enumeration, or retrieved for further molecular analysis.

“This has been a collaborative merging of our extensive experience in diagnostic device development and Clearbridge BioMedics’ expertise in cancer research and diagnostics—and it’s led to breakthrough technology that will have a huge impact on a lot of people’s lives,” said John Pritchard, head of diagnostics at Cambridge Consultants of Altran; “Our systems engineering approach, coupled with our skills in fluidics, software, and compliance, has enabled us to work quickly and efficiently with Clearbridge BioMedics—even though we are thousands of miles apart.” Clearbridge BioMedics also collaborated with the National University of Singapore and the Singapore-MIT Alliance for Research and Technology Center.

The new system, designed for both research and diagnostics applications, will be undergoing regulatory approval in the US and Europe. “Once approved, it will be one of the world’s first label-free CTC enrichment systems for diagnostic use. Clearbridge BioMedics believes this system will be an ideal companion diagnostic system that complements various cancer therapies,” said Johnson Chen, cofounder and managing director of Clearbridge BioMedics.

Related Links:

Clearbridge BioMedics
Cambridge Consultants



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Diagram illustrates the innovative process that could lead to more effective drugs against influenza infection (Photo courtesy of the Hebrew University of Jerusalem).

Researchers Show How the Influenza Virus Blocks Natural Killer Cell Recognition

A team of molecular virologists has described how the influenza virus evolved a defense mechanism to protect it from attack by the immune system's natural killer (NK) cells. The recognition of pathogen-infected... Read more

Drug Discovery

view channel
Image: Synthetic ion transporters can induce apoptosis by facilitating chloride anion transport into cells (Photo courtesy of the University of Texas, Austin).

Experimental Drug Kills Cancer Cells by Interfering with Their Ion Transport Mechanism

An experimental anticancer drug induces cells to enter a molecular pathway leading to apoptosis by skewing their ion transport systems to greatly favor the influx of chloride anions. To promote development... Read more

Therapeutics

view channel
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).

New Drug Triggers Liver Regeneration After Surgery

Investigators have revealed that an innovative complement inhibitor decreases complement-mediated liver cell death, and actually stimulates postsurgery liver regrowth in mice. Liver cancer often results... Read more

Lab Technologies

view channel

Genome-Wide Mutation-Searching Computational Software Designed for Genomic Medicine

Analysis software cross-references a patient’s symptoms with his genome sequence to help physicians in the diagnosis of disease. This software was created by a team of scientists from A*STAR’s Genome Institute of Singapore (GIS), led by Dr. Pauline Ng. The research findings were published August 3, 2014, in the journal... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.